The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
From Combinatorial Chemistry to Cancer-Targeting Peptides
Abstract
Several monoclonal antibodies that target cell surface receptors have gained approval by the U.S. Food and Drug Administration and are widely used in the treatment of some cancers. These include but are not limited to the anti-CD20 antibody Rituximab, used in lymphoma treatment, as well as anti-HER-2 antibody for breast cancer therapy. The efficacy of this cancer immunotherapy modality is, however, limited by the large size of the antibody (160 kd) and its relatively nonspecific binding to the reticuloendothelial system. This latter property is particularly problematic if the antibody is used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to the tumor site. Peptides, peptidomimetic, or small molecules are thus attractive as alternative cell surface targeting agents for cancer imaging and therapy. Cancer cell surface targeting peptides can be derived from known native peptide hormones such as somatostatin and bombesin, or they can be identified through screening combinatorial peptide libraries against unknown cell surface receptor targets. Phage-display peptide library and one-bead one-compound (OBOC) combinatorial library methods have been successfully used to discover peptides that target cancer cells or tumor blood vessel endothelial cells. The phage-display peptide library method, because of its biological nature, can only display l-amino acid peptides. In contrast, the OBOC combinatorial library method allows for bead-surface display of peptides that contain l-amino acids, d-amino acids, unnatural amino acids, or other organic moieties. We have successfully used the OBOC method to discover and optimize ligands against unique cell surface receptors of prostate cancer, T- and B-cell lymphoma, as well as ovarian and lung cancers, and we have used some of these peptides to image xenografts in nude mice with high specificity. Here, we (i) review the literature on the use of phage-display and OBOC combinatorial library methods to discover cancer and tumor blood vessel targeting ligands, and (ii) report on the use of an ovarian cancer targeting ligand, OA02, as an in vivo PET imaging probe in a xenograft model in nude mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library.
Koivunen, E., Gay, D. A., & Ruoslahti, E. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80715-7 · Cited by 344
Cited by
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Self‐Assembled Peptide‐Based Nanomaterials for Biomedical Imaging and Therapy
Qi, G., Gao, Y., Wang, L., & Wang, H. (2018) · Advanced Materials · doi:10.1002/adma.201703444 · Cited by 527
Cell-penetrating and cell-targeting peptides in drug delivery
Vivès, E., Schmidt, J., & Pèlegrin, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.03.001 · Cited by 441
Combinatorial chemistry in drug discovery
Liu, R., Li, X., & Lam, K. S. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.03.017 · Cited by 332
Self-citationPeptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis
Lee, S., Xie, J., & Chen, X. (2010) · Chemical Reviews · doi:10.1021/cr900361p · Cited by 324
Peptide-Based Probes for Targeted Molecular Imaging
Lee, S., Xie, J., & Chen, X. (2010) · Biochemistry · doi:10.1021/bi901135x · Cited by 310
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
Wang, S., Placzek, W. J., Stebbins, J. L., Mitra, S., Noberini, R., Koolpe, M., Zhang, Z., Dahl, R., Pasquale, E. B., & Pellecchia, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201743s · Cited by 94
Metadata
- Authors
- Aina, O. H., Liu, R., Sutcliffe, J. L., Marik, J., Pan, C.-X., & Lam, K. S.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-09-20
- Volume
- 4
- Issue
- 5
- Pages
- 631-651
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2038609448
- Cited by
- 285
- References
- 1
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.